Literature DB >> 8486718

A cytotoxic ribonuclease. Study of the mechanism of onconase cytotoxicity.

Y Wu1, S M Mikulski, W Ardelt, S M Rybak, R J Youle.   

Abstract

Onconase, or P-30, is a protein initially purified from extracts of Rana pipiens oocytes and early embryos based upon its anticancer activity both in vitro and in vivo. It is a basic single-chain protein with an apparent molecular mass of 12,000 daltons and is homologous to RNase A. In cultured 9L glioma cells, onconase inhibits protein synthesis with an IC50 of about 10(-7) M. The inhibition of protein synthesis correlates with cell death determined by clonogenic assays. 125I-Labeled onconase binds to specific sites on cultured 9L glioma cells. Scatchard analysis of the binding data shows that onconase appears to bind to cells with two different affinities, one with a Kd of 6.2 x 10(-8) and another of 2.5 x 10(-7) M. Each cell could bind about 3 x 10(5) molecules of onconase at each of the two affinity sites. The low affinity Kd is similar to the IC50 for onconase toxicity. Onconase also demonstrates a saturability of cytotoxicity at a concentration that would saturate the low affinity binding site. Incubation at 4 degrees C increased the binding of onconase to cells relative to 37 degrees C binding and also increased the sensitivity of cells to onconase toxicity, indicating that receptor binding may be an initial step in cell toxicity. Onconase cytotoxicity can be blocked by metabolic inhibitors, NaN3 and 2-deoxyglucose, and cytotoxicity is potentiated 10-fold by monensin. Ribonuclease activity appears necessary for onconase toxicity because alkylated onconase, which only retains 2% of the ribonuclease activity, was at least 100-fold less potent in inhibiting protein synthesis in cells. Onconase inhibition of protein synthesis in 9L cells coincides with the degradation of cellular 28 S and 18 S rRNA. In contrast to RNase A, onconase is resistant to two RNase inhibitors, placental ribonuclease inhibitor and Inhibit-Ace. Northern hybridization with placental ribonuclease inhibitor cDNA probe indicates that 9L glioma cells contain endogenous placental ribonuclease inhibitor mRNA. Based on these results, we propose that onconase toxicity results from onconase binding to cell surface receptors, internalization to the cell cytosol where it degrades ribosomal RNA, inhibiting protein synthesis and causing cell death.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8486718

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  60 in total

1.  Induction of differentiation of leukaemic (HL-60) or prostate cancer (LNCaP, JCA-1) cells potentiates apoptosis triggered by onconase.

Authors:  H D Halicka; T Murakami; C N Papageorgio; A Mittelman; S M Mikulski; K Shogen; Z Darzynkiewicz
Journal:  Cell Prolif       Date:  2000-12       Impact factor: 6.831

2.  Second generation antitumour human RNase: significance of its structural and functional features for the mechanism of antitumour action.

Authors:  S Di Gaetano; G D'alessio; R Piccoli
Journal:  Biochem J       Date:  2001-08-15       Impact factor: 3.857

Review 3.  Cancer chemotherapy--ribonucleases to the rescue.

Authors:  P A Leland; R T Raines
Journal:  Chem Biol       Date:  2001-05

4.  Mutations abrogating the RNase activity in glycoprotein E(rns) of the pestivirus classical swine fever virus lead to virus attenuation.

Authors:  G Meyers; A Saalmüller; M Büttner
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

Review 5.  Ribonuclease inhibitor: structure and function.

Authors:  Kimberly A Dickson; Marcia C Haigis; Ronald T Raines
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2005

6.  Cytostatic and cytotoxic properties of Amphinase: a novel cytotoxic ribonuclease from Rana pipiens oocytes.

Authors:  Barbara Ardelt; Wojciech Ardelt; Piotr Pozarowski; Jan Kunicki; Kuslima Shogen; Zbigniew Darzynkiewicz
Journal:  Cell Cycle       Date:  2007-09-12       Impact factor: 4.534

7.  Secretory ribonucleases are internalized by a dynamin-independent endocytic pathway.

Authors:  Marcia C Haigis; Ronald T Raines
Journal:  J Cell Sci       Date:  2003-01-15       Impact factor: 5.285

8.  Structural features for the mechanism of antitumor action of a dimeric human pancreatic ribonuclease variant.

Authors:  Antonello Merlino; Giovanna Avella; Sonia Di Gaetano; Angela Arciello; Renata Piccoli; Lelio Mazzarella; Filomena Sica
Journal:  Protein Sci       Date:  2009-01       Impact factor: 6.725

9.  Ribonuclease A variants with potent cytotoxic activity.

Authors:  P A Leland; L W Schultz; B M Kim; R T Raines
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

10.  Intraspecies regulation of ribonucleolytic activity.

Authors:  R Jeremy Johnson; Luke D Lavis; Ronald T Raines
Journal:  Biochemistry       Date:  2007-10-23       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.